Sharemaestro Newsreel

Dividend Roundup: Wells Fargo, Merck, Citigroup, Carnival Corp, and more

This dividend roundup highlights recent activity including increased payouts from Wells Fargo and Union Pacific, and declarations from Merck and Marathon Petroleum. The article also anticipates upcoming dividend activity from companies like Citigroup.

Novo Nordisk Stock Sinks on Disappointing Heart Drug Trial Results

Novo Nordisk's U.S.-listed shares fell sharply premarket after its heart drug ziltivekimab failed to meet expectations in a Phase 3 trial. The drug, aimed at inflammatory conditions, did not reduce major adverse cardiovascular events in patients despite showing target engagement. While this outcome won't …

Johnson & Johnson to pay $5.5bn settlement in talc cancer lawsuit

Johnson & Johnson has agreed to a $5.5 billion settlement to resolve tens of thousands of lawsuits alleging its talc products caused ovarian cancer. This landmark deal covers approximately 76,000 claims and aims to conclude a contentious, decade-long legal battle. The company maintains its …

J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

Johnson & Johnson has secured an option to acquire Sail Biomedicines, an "in vivo" CAR-T developer, for an agreed-upon price that could reach $2.58 billion. J&J is initially investing $785 million, including a $465 million equity investment, to advance Sail's preclinical lead program, SAIL-0839, …

Organon (OGN) Lags Q2 Earnings Estimates

Orographic Financial Advisors LLC Acquires New Holdings in Organon & Co. $OGN

AbbVie (ABBV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

ABBV Beats on Q2 Earnings & Sales, Cuts '26 EPS View, Stock Down

AbbVie (ABBV) Q2 Earnings and Revenues Beat Estimates

AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.

Organon & Co. (NYSE:OGN) Issues Earnings Results, Misses Expectations By $0.02 EPS

Organon & Co. (NYSE:OGN) to Issue $0.02 Quarterly Dividend

Organon & Co. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?

Bristol Myers Squibb (BMY) Stock Shrugs Off Profit Surge And Patent Risk

Biogen (BIIB) Stock Revenue Holds While Margins and EPS Retreat

Biogen's Q2 2026 earnings showed steady revenue but a significant decline in net income and EPS due to margin squeeze and acquisition costs. While growth products like SYFOVRE and EMPAVELI are performing well, the company's profitability is being impacted by R&D and deal charges. …

REG - AstraZeneca PLC - Datroway approved in EU for TNBC

AstraZeneca and Daiichi Sankyo's Datroway (datopotamab deruxtecan) has received approval in the EU as a monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. This approval is based on …

Sanofi’s New CEO Highlights Pipeline Prioritization

Sanofi's new CEO, Belén Garijo, has initiated an accelerated transformation roadmap focused on commercial strengths and R&D pipeline improvements. The company aims to diversify its portfolio and reduce reliance on top-selling Dupixent by prioritizing new product growth and strategically assessing its pipeline, including discontinuing …

Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline

Sanofi's shares dropped sharply after its new CEO, Belen Garijo, admitted the company faces challenges in filling its drug pipeline, necessitating increased spending and potential deals. Garijo announced a revamp of the research-and-development operations and an intention to intensify dealmaking to improve growth prospects. …

FIRST AMGEN SCHOLARS PROGRAM IN INDIA LAUNCHES AT IIIT HYDERABAD

Amgen has launched its first Amgen Scholars Program in India at the International Institute of Information Technology Hyderabad (IIIT Hyderabad), a two-year commitment to foster scientific innovation through AI-enabled research in healthcare and drug discovery. The inaugural cohort includes 10 undergraduate scholars from various …

Merck & Co., Inc. Securities Fraud Class Action Lawsuit Pending

A class action securities lawsuit has been filed against Merck & Co., Inc. (NYSE:MRK) alleging securities fraud between February 3, 2022, and February 3, 2025. The lawsuit claims Merck made misleading statements regarding projected $11 billion in Gardasil sales by 2030, which it later …

How Investors May Respond To Amgen (AMGN) Repatha Expansion and 2026 Dividend Declaration

Amgen (AMGN) recently declared a Q3 2026 dividend of US$2.52 per share and received a positive opinion from the European Medicines Agency's CHMP for expanding Repatha's use in high-risk cardiovascular prevention. This article discusses how these developments, particularly the Repatha expansion, could influence Amgen's …

Grifols Half-Year 2026 Results: Profit Jumps as Refinancing Bolsters Balance Sheet

Grifols reported a significant increase in revenue and net profit for the first half of 2026, driven by Biopharma growth and immunoglobulin sales. The company also strengthened its financial position through a major refinancing, extending debt maturities and receiving multiple credit rating upgrades. These …

Amarin (AMRN) Stock Hinges On Cash Flow As Revenue Retreat Deepens

Grifols, S.A. Pref Class B Revenue Breakdown – MUN:G0F0

Grifols, S.A. Pref Class B (MUN:G0F0) generated 7.52 billion EUR in revenue last year, with its Biopharma segment being the top performer, contributing 6.49 billion EUR. The United States and Canada were the largest regional contributors, accounting for 4.25 billion EUR of the company's …

Amarin Corp PLC (AMRN) Q2 2026 Earnings Call Highlights: Strategic Growth Amidst Revenue Challenges

Amarin Corp PLC reported its Q2 2026 earnings, showcasing strategic growth in international markets despite an overall revenue decrease to $42.2 million from $72.7 million year-over-year. The company highlighted successful dual commercial strategies, including significant international expansion of VASCEPA, and improved its cash position …

Why Biogen (BIIIB) Is Up 5.8% After Q2 Revenue Beat And Raised 2026 Guidance - And What's Next

Biogen (BIIB) saw its stock rise by 5.8% after reporting strong Q2 2026 results with revenue beating expectations and raised 2026 guidance. This performance was driven by its expanding growth portfolio and the Apellis acquisition, which are offsetting declining sales in legacy multiple sclerosis …

Merck & Company, Inc. Revenue Breakdown – NYSE:MRK

Merck & Company, Inc. (NYSE: MRK) generated $65.01 billion in revenue last year, with its Pharmaceutical segment contributing $58.14 billion. The United States was the largest geographical contributor, accounting for $36.51 billion of the revenue. These figures highlight the company's strong performance in its …

Amgen declares $2.52 quarterly dividend for Q3 2026

Amgen Inc. announced a quarterly dividend of $2.52 per share for the third quarter of 2026. The dividend is scheduled to be paid on September 11, 2026, to stockholders on record as of August 21, 2026. Amgen is a prominent biotechnology company based in …

AMGEN ANNOUNCES 2026 THIRD QUARTER DIVIDEND

Amgen (NASDAQ:AMGN) has announced that its Board of Directors declared a dividend of $2.52 per share for the third quarter of 2026. This dividend will be distributed on September 11, 2026, to all stockholders of record as of the close of business on August …

Amgen Sets Sept. 11 Payment Date for $2.52 Dividend

Amgen (NASDAQ: AMGN) has declared a cash dividend of $2.52 per share for the third quarter of 2026. This dividend is scheduled to be paid on September 11, 2026, to stockholders who are on record as of the close of business on August 21, …

Novartis AG Lobbyists, 2023

This article from OpenSecrets.org details the lobbying activities of Novartis AG in 2023. It lists 73 lobbyists hired by Novartis, with 56 (76.7%) of them having previous federal government experience, indicating a significant "revolving door" phenomenon. The report also names the firms that employed …

BIIB Maintains Rating by Morgan Stanley -- Price Target Raised to $231

Morgan Stanley has reiterated its "Equal-Weight" rating for Biogen (BIIB) and increased its price target from $222.00 to $231.00. Despite this positive adjustment, GuruFocus's GF Value™ indicates that Biogen is currently 7.2% overvalued. The company's GF Score™ of 68/100 points to strong profitability and …

Bristol-Myers, Merck win FDA review for Reblozyl label expansion

The FDA has accepted Bristol-Myers Squibb's marketing application for an expanded U.S. label for its anemia therapy, Reblozyl. This drug was developed in partnership with Merck. The announcement was made during Bristol-Myers Squibb's Q2 2026 financial report.

New CEO Garijo sketches out vision to reverse Sanofi's fortunes as Q2 delivers impressive sales beat

Sanofi's new CEO, Belén Garijo, outlined her vision to revitalize the company during her inaugural earnings call, following a strong Q2 performance with sales exceeding forecasts by 8%. While the immunology drug Dupixent significantly contributed to this success, Garijo emphasized the need to diversify …

Sanofi CEO ‘looking deeply’ at pipeline as clearout continues

Sanofi's new CEO, Belén Garijo, is undertaking a rigorous assessment of the company's late-stage pipeline, leading to the discontinuation of several previously touted drug candidates. Her strategy focuses on investing where science is strongest and unmet medical needs are greatest, while also considering acquisitions …